EDITORIAL

228  O-linked β-N-acetylglucosaminylation may be a key regulatory factor in promoting osteogenic differentiation of bone marrow mesenchymal stromal cells
  Zhou XC, Ni GX

232  Understanding host-graft crosstalk for predicting the outcome of stem cell transplantation
  Labusca L, Zugun-Eloae F

237  High glucose microenvironment and human mesenchymal stem cell behavior
  Mateen MA, Alaagib N, Haider KH

MINIREVIEWS

245  How mesenchymal stem cells transform into adipocytes: Overview of the current understanding of adipogenic differentiation

ORIGINAL ARTICLE

Retrospective Study

257  Long-term outcome of stem cell transplantation with and without anti-tumor necrotic factor therapy in perianal fistula with Crohn’s disease
  Park MY, Yoon YS, Park JH, Lee JL, Yu CS

Basic Study

267  Low-intensity pulsed ultrasound reduces alveolar bone resorption during orthodontic treatment via Lamin A/C-Yes-associated protein axis in stem cells

287  Self-assembly of differentiated dental pulp stem cells facilitates spheroid human dental organoid formation and prevascularization
  Liu F, Xiao J, Chen LH, Pan YY, Tian JZ, Zhang ZR, Bai XC

305  Evaluation of genetic response of mesenchymal stem cells to nanosecond pulsed electric fields by whole transcriptome sequencing
  Lin JJ, Ning T, Jia SC, Li KJ, Huang YC, Liu Q, Lin JH, Zhang XT
ABOUT COVER
Editorial Board Member of World Journal of Stem Cells, Yu-Hong Li, PhD, Associate Professor, Department of Cell Biology, Army Medical University, Chongqing 400038, China. liyuhongtmmu@hotmail.com

AIMS AND SCOPE
The primary aim of World Journal of Stem Cells (WJSC, World J Stem Cells) is to provide scholars and readers from various fields of stem cells with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJSC publishes articles reporting research results obtained in the field of stem cell biology and regenerative medicine, related to the wide range of stem cells including embryonic stem cells, germline stem cells, tissue-specific stem cells, adult stem cells, mesenchymal stromal cells, induced pluripotent stem cells, embryonal carcinoma stem cells, hemangioblasts, lymphoid progenitor cells, etc.

INDEXING/ABSTRACTING
The WJSC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, PubMed, PubMed Central, Scopus, Biological Abstracts, BIOSIS Previews, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJSC as 4.1; IF without journal self cites: 3.9; 5-year IF: 4.5; Journal Citation Indicator: 0.53; Ranking: 15 among 29 journals in cell and tissue engineering; Quartile category: Q3; Ranking: 99 among 191 journals in cell biology; and Quartile category: Q3. The WJSC’s CiteScore for 2022 is 8.0 and Scopus CiteScore rank 2022: Histology is 9/57; Genetics is 68/325; Genetics (clinical) is 19/90; Molecular Biology is 119/380; Cell Biology is 95/274.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Xiang-Di Zhang; Production Department Director: Xu Guo; Cover Editor: Jia-Ru Fan.
O-linked β-N-acetylglucosaminylation may be a key regulatory factor in promoting osteogenic differentiation of bone marrow mesenchymal stromal cells

Xu-Chang Zhou, Guo-Xin Ni

Abstract
Cumulative evidence suggests that O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) plays an important regulatory role in pathophysiological processes. Although the regulatory mechanisms of O-GlcNAcylation in tumors have been gradually elucidated, the potential mechanisms of O-GlcNAcylation in bone metabolism, particularly, in the osteogenic differentiation of bone marrow mesenchymal stromal cells (BMSCs) remains unexplored. In this study, the literature related to O-GlcNAcylation and BMSC osteogenic differentiation was reviewed, assuming that it could trigger more scholars to focus on research related to O-GlcNAcylation and bone metabolism and provide insights into the development of novel therapeutic targets for bone metabolism disorders such as osteoporosis.

Key Words: O-GlcNAcylation; Osteogenic differentiation; Bone marrow mesenchymal stromal cells; Osteoporosis

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
**Core Tip:** O-linked β-N-acetylglucosaminylation (O-GlcNAcylation), an important post-translational modification of proteins, widely involved in the regulation of biological processes such as signal transduction and proteasomal degradation, plays an essential role in the initiation and progression of various diseases such as bone metabolism. In this study, we emphasized that maintaining appropriate levels of O-GlcNAcylation is beneficial for the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). Insufficient or excessive levels of O-GlcNAcylation are detrimental to BMSC osteogenic differentiation.

**Citation:** Zhou XC, Ni GX. O-linked β-N-acetylglucosaminylation may be a key regulatory factor in promoting osteogenic differentiation of bone marrow mesenchymal stromal cells. *World J Stem Cells* 2024; 16(3): 228-231

**URL:** https://www.wjgnet.com

**DOI:** https://dx.doi.org/10.4252/wjsc.v16.i3.228

**INTRODUCTION**

Bone marrow mesenchymal stromal cells (BMSCs), important precursors of osteoblastic lineage cells, are pluripotent stem cells with self-renewal, immunomodulatory, and multidifferentiation potentials[1]. As the major source of osteoblasts, BMSCs are important contributors to the bone tissue repair process. The abnormal osteogenic differentiation of BMSCs is an important cause of bone metabolism-related diseases, including osteoporosis[2,3]. O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) is an important post-translational modification in which involves the attachment of a single O-GlcNAc moiety to Ser or Thr residues of cytoplasmic, nuclear, and mitochondrial proteins. O-GlcNAcylation can regulate fundamental cellular processes ranging from gene transcription and translation to protein localization, interaction, and degradation[4]. The donor for O-GlcNAcylation is a nucleoside sugar, such as uridine diphosphate GlcNAc (UDP-GlcNAc). UDP-GlcNAc, a key metabolite produced by the hexosamine biosynthetic pathway, is synthesized by consumption of uridine triphosphate, glucose, glutamine, and acetyl-CoA[5]. As a ubiquitous post-translational modification of proteins, O-GlcNAcylation is regulated by two conserved enzymes: O-GlcNac transferase (OGT), which can add O-GlcNAc to proteins, and O-GlcNAc enzyme (OGA), which can remove O-GlcNAc from proteins. O-GlcNAcylation maintains optimal homeostatic balance through mutual regulation of OGT and OGA[4]. However, uncoupled OGT and OGA homeostasis have been shown to be associated with the pathogenesis of multiple human diseases, including bone metabolic diseases. Emerging evidence shows that O-GlcNAc modification is closely related to the osteogenic differentiation of BMSCs[6].

BMSCs have the potential to differentiate into osteoblasts, adipocytes, and chondrocytes[7,8]. A recent study showed that OGT knockout in mouse BMSCs inhibited bone formation while promoting bone marrow adipogenesis[9], indicating that O-GlcNAcylation may be a key regulatory factor affecting the differentiation fate of BMSCs. Runt-related transcription factor 2 (RUNX2) is a member of the polyomavirus enhancer-binding protein 2/core-binding factor superfamily[10,11]. The balance between osteogenesis and adipogenic differentiation in BMSC is coordinated regulated by transcription factors Runx2 and CCAAT/enhancer-binding protein C (C/EBPβ) through O-GlcNAc post-translational modifications. The increased O-glycosylation of Runx2 is not only critical for osteogenic differentiation, but also promotes B lymphocytes by activating interleukin-7. Knockdown of OGT can activate the transcriptional activity of C/EBPβ to promote the adipogenic differentiation of BMSCs[12,13], and upregulate the expression of myelopoietic stem cell factor encoded by the Kit gene, thereby increasing myopoiesis[14-17]. In addition, Kim et al.[6] observed that elevated protein O-GlcNAc modification enhances the binding of Runx2 to Ose2 by promoting the transcriptional activity of Runx2 and inducing an increase in the expression of the osteoblast-specific marker osteocalcin (OCN)[18-21]. Another study reported that the osteogenic differentiation marker bone morphogenetic protein 2/7 reduced OGA activity[18]. During osteogenic differentiation process of BMSC, the overall level of O-GlcNAcylation increases. Pharmacological inhibition of OGA promotes the expression of osteogenic differentiation makers, including alkaline phosphatase (ALP), OCN, and bone sialoprotein[6,18,22,23].

Hyperglycemia is reported to be closely related to bone formation inhibition and is a major factor in diabetic osteoporosis[24-27]. Previous studies have shown that high blood sugar levels increase the O-GlcNAcylation of proteins. Abnormal regulation of O-GlcNAcylation is closely associated with the pathogenesis of diabetes mellitus[28]. Therefore, hyperglycemia-induced excessive and abnormal O-GlcNAcylation may lead to reduced osteogenic differentiation and diabetic osteoporosis. Gu et al.[29] demonstrated that excessive O-GlcNAcylation induced by high glucose, glucosamine, or GlcNAc treatment or OGT overexpression can reduce the expression levels of osteoblast markers, such as ALP, type I collagen, OCN, Runx2, and osterix, thereby inhibiting osteogenic differentiation. These results are consistent with the phenotypic reduction in bone formation observed in patients with type 2 diabetes. However, other studies have shown that the upregulation of O-GlcNAcylation through supplementation with OGA inhibitors promotes osteogenic differentiation and increases Runx2 transcriptional activity and matrix mineralization[6,18]. One explanation for aforementioned difference is that the effects of metabolic treatment (high concentration glucose treatment) and drug treatment (OGA inhibitors) may be different. Pharmacological inhibition of OGA increases the O-GlcNAcylation level by breaking the dynamic on/off cycle, whereas metabolic treatment or OGT overexpression increases the O-GlcNAcylation level by shifting the balance toward modification[30].
CONCLUSION

The osteogenic differentiation of BMSCs requires a moderate increase of O-GlcNAcylation, and an excessive increase in overall O-GlcNAcylation may inhibit the osteogenic differentiation of BMSCS. Therefore, the overall O-GlcNAcylation level should be maintained within an optimal range to protect normal cellular functions. The precise regulation of O-GlcNAcylation may be an effective strategy for promoting the osteogenic differentiation of BMSCs, correcting abnormal bone metabolism, and preventing bone-related diseases. Further elucidation of the potential regulatory mechanism between O-GlcNAcylation and the osteogenic differentiation of BMSCS will help to better understand the pathogenesis of bone metabolic diseases and provide novel ideas for the treatment and prevention of bone metabolic diseases.

FOOTNOTES

Author contributions: Zhou XC and Ni GX designed and coordinated the study; Zhou XC wrote the manuscript; and all authors approved the final version of the article.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Xu-Chang Zhou 0000-0003-1390-7659; Guo-Xin Ni 0000-0001-9181-8155.

S-Editor: Wang J

L-Editor: A

P-Editor: Yuan YY

REFERENCES


BMP2-Induced Osteogenic Differentiation of C2C12 Cells. 2007; 10.2337/diacare.29.02.06.dc05-1353

Mineral density and calcaneal quantitative ultrasound than nondiabetic women. 10.1007/s00223-003-0023-7

GlcNAcylation drives calcium signaling toward osteoblast differentiation: A bioinformatics-oriented study. 2015; 31779679

Differentiation of human cartilage endplate stem cells from bone marrow mesenchymal stem cells. Progenitor Differentiation. 2016; 2006; 194-202 [PMID: 19478079 DOI: 10.1074/jbc.R114.591560]